Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07357103 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)

Study acronym: SPIRIT-ALT
StatusNot Yet Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The usual first treatment for Pneumocystis jirovecii pneumonia (PCP) is an antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX). However, some patients cannot take this medication because of allergies, side effects, or lack of response. This study asks the question: When TMP-SMX cannot be used, which alternative treatment for PCP provides the best balance of effectiveness and safety?
Trial Details
NCT Number NCT07357103
Lead Sponsor McGill University Health Centre/Research Institute of the McGill University Health Centre
Conditions
(from sponsor)		 Pneumocystis, Pneumocystis Infection, Pneumocystis Carinii Infection, Pneumocystis Carinii; Infection, Resulting From HIV Disease, Pneumocystis Jirovecii Pneumonia, Pneumocystis Jirovecii Infection, Pneumocystosis Associated With AIDS, Pneumocystosis; Pneumonia (Etiology)
Related terms Infections, Pneumocystis Infections, Pneumonia, Pneumonia, Pneumocystis
Enrollment 416 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov